Immunotherapy

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion
Robert J Oldham, C Ian Mockridge, Sonya James, Patrick J Duriez, H T Claude Chan, Kerry L Cox, Vicentiu A Pitic, Martin J Glennie, Mark S Cragg

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000619; DOI: 10.1136/jitc-2020-000619
Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication
Wei Wang, Meihong Wu, Minglu Liu, Zhengqing Yan, Guoqiang Wang, Dongliang Mao, Mei Wang

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000793; DOI: 10.1136/jitc-2020-000793
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura, Shumei Kato, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000438; DOI: 10.1136/jitc-2019-000438
Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis
Ssu-Hsueh Tseng, Sung-Taek Park, Brandon Lam, Ya-Chea Tsai, Max A Cheng, Emily Farmer, Deyin Xing, Chien-Fu Hung

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000480; DOI: 10.1136/jitc-2019-000480
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Karin M Knudson, Kristin C Hicks, Yohei Ozawa, Jeffrey Schlom, Sofia R Gameiro

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000493; DOI: 10.1136/jitc-2019-000493
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8⁺ T cell responses capable of curing multi-focal cancer
Joshua M Walker, Annah S Rolig, Deborah H Charych, Ute Hoch, Melissa J Kasiewicz, Daniel C Rose, Michael J McNamara, Ian F Hilgart-Martiszus, William L Redmond

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000464; DOI: 10.1136/jitc-2019-000464
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
Claire Smalley Rumfield, Samuel T Pellom, Y Maurice Morillon II, Jeffrey Schlom, Caroline Jochems

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000612; DOI: 10.1136/jitc-2020-000612
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Kartik Sehgal, Andreas Varkaris, Hollis Viray, Paul A VanderLaan, Deepa Rangachari, Daniel B Costa

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000697; DOI: 10.1136/jitc-2020-000697
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael Overman, Milind Javle, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Al B Benson, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu, Anirban Maitra

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000587; DOI: 10.1136/jitc-2020-000587
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Tanja Stüber, Razieh Monjezi, Lars Wallstabe, Johanna Kühnemundt, Sarah Louise Nietzer, Gudrun Dandekar, Achim Wöckel, Hermann Einsele, Jörg Wischhusen, Michael Hudecek

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000676; DOI: 10.1136/jitc-2020-000676

Main menu

Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy

Pages